Abzena PLC Change of Adviser (3286Z)
30 Agosto 2018 - 2:28PM
UK Regulatory
TIDMABZA
RNS Number : 3286Z
Abzena PLC
30 August 2018
Abzena plc
Change of Adviser
Cambridge, UK, 30 August 2018 - Abzena plc (AIM: ABZA, 'Abzena'
or the 'Group'), a life sciences group providing services and
technologies to enable development and manufacture of
biopharmaceutical products, announces the appointment of N+1 Singer
as its Nominated Adviser and Sole Broker with immediate effect.
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive Officer Julian
Smith, Chief Financial Officer +44 1223 903498
N+1 Singer
Aubrey Powell / Ben Farrow +44 20 7496 3000
Instinctif Partners +44 20 7457 2020
Melanie Toyne Sewell / Alex Shaw abzena@instinctif.com
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on ABZENA Inside products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
-- Biology research studies, including immunogenicity assessment
of candidate biopharmaceutical products and bioassay
development;
-- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
-- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of
biopharmaceuticals, including monoclonal antibodies and recombinant
proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research
services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel payloads for ADC development;
-- GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and
-- GMP analytical services for biopharmaceutical manufacturing projects.
For more information, please see www.abzena.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPZMGFRNGVGRZM
(END) Dow Jones Newswires
August 30, 2018 13:28 ET (17:28 GMT)
Abzena (LSE:ABZA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Abzena (LSE:ABZA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024